TY - JOUR
T1 - [¹¹C] choline as a potential PET/CT biomarker of liver cirrhosis
T2 - A prospective pilot study
AU - Schmilovitz-Weiss, Hemda
AU - Boltin, Doron
AU - Groshar, David
AU - Domachevsky, Liran
AU - Rosenbaum, Eli
AU - Issa, Nidal
AU - Sapoznikov, Boris
AU - Goren, Idan
AU - Issachar, Assaf
AU - Cohen-Naftaly, Michal
AU - Weiss, Avraham
AU - Gingold-Belfer, Rachel
AU - Bernstine, Hanna
N1 - Publisher Copyright:
© 2020 Editrice Gastroenterologica Italiana S.r.l.
PY - 2021/6
Y1 - 2021/6
N2 - Aim of the study: To compare [¹¹C] choline PET/CT findings between patients with cirrhosis and normal liver controls. Methods: Included 11 patients with cirrhosis and 14 controls. All underwent a dynamic [11C] choline PET/CT. The maximal standard uptake values (SUVmax), the area under the curve (AUC) and kinetic parameters (K1 and K2), clinical and laboratory data, were compared between groups. Results: Patients mean age was 68.4 ± 10.7 and controls, 69.7 ± 7.3 years. Mean SUVmax was higher in patients than controls (right lobe, 10.06 ± 12 vs. 6.3 ± 1.6, P = 0.011; left lobe, 8.6 ± 11.6 vs. 5.4 ± 0.9, P = 0.024; spleen 17.99 ± 27.8 vs. 13.4 ± 2.6, P = 0.027; kidney, 35.9 ± 59.5 vs. 19.3 ± 4.8, P = 0.025) and also AUC values (right lobe, 13,538 ± 20,020 vs. 8427.3 ± 1557.9, P = 0.026; left lobe 12,304 ± 18,871 vs. 6878.9 ± 1294.3, P = 0.024; spleen, 12,875 ± 17,930 vs. 8263.9 ± 1279.2, P = 0.023; kidney, 24,623 ± 36,025 vs. 13,667 ± 3873.9, P = 0.032). No difference in kinetic parameters was found. No correlations between severity of clinical signs and imaging-derived parametric data were found among patients with cirrhosis. Conclusions: [11C] choline PET/CT may serve as a noninvasive biomarker for patients with cirrhosis.
AB - Aim of the study: To compare [¹¹C] choline PET/CT findings between patients with cirrhosis and normal liver controls. Methods: Included 11 patients with cirrhosis and 14 controls. All underwent a dynamic [11C] choline PET/CT. The maximal standard uptake values (SUVmax), the area under the curve (AUC) and kinetic parameters (K1 and K2), clinical and laboratory data, were compared between groups. Results: Patients mean age was 68.4 ± 10.7 and controls, 69.7 ± 7.3 years. Mean SUVmax was higher in patients than controls (right lobe, 10.06 ± 12 vs. 6.3 ± 1.6, P = 0.011; left lobe, 8.6 ± 11.6 vs. 5.4 ± 0.9, P = 0.024; spleen 17.99 ± 27.8 vs. 13.4 ± 2.6, P = 0.027; kidney, 35.9 ± 59.5 vs. 19.3 ± 4.8, P = 0.025) and also AUC values (right lobe, 13,538 ± 20,020 vs. 8427.3 ± 1557.9, P = 0.026; left lobe 12,304 ± 18,871 vs. 6878.9 ± 1294.3, P = 0.024; spleen, 12,875 ± 17,930 vs. 8263.9 ± 1279.2, P = 0.023; kidney, 24,623 ± 36,025 vs. 13,667 ± 3873.9, P = 0.032). No difference in kinetic parameters was found. No correlations between severity of clinical signs and imaging-derived parametric data were found among patients with cirrhosis. Conclusions: [11C] choline PET/CT may serve as a noninvasive biomarker for patients with cirrhosis.
KW - Biomarker
KW - Cirrhosis
KW - PET/CT
KW - [¹¹C] choline
UR - http://www.scopus.com/inward/record.url?scp=85097058230&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2020.11.013
DO - 10.1016/j.dld.2020.11.013
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33272861
AN - SCOPUS:85097058230
SN - 1590-8658
VL - 53
SP - 753
EP - 759
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 6
ER -